Text: Small Text  Normal Text  Large Text  Larger Text

    Blog Archive

    PrevPrevMay 2013NextNext
    SMTWTFS
       1234
    567891011
    12131415161718
    19202122232425
    262728293031

    Canada Reportedly Ready to Cave on CETA Drug Patent Demands

    PDF  | Print |  E-mail
    Wednesday November 14, 2012
    The Canadian Press reports that Canada is ready to cave to European demands for changes to patent rules that could cost Canadians hundreds of millions of dollars in higher health care costs. The ministerial meeting on the remaining CETA issues is set for next week.

    Tags:
    , ,
    Share: Slashdot, Digg, Del.icio.us, Newsfeeder, Reddit, StumbleUpon, TwitterTagsShare
     

    EU Drops Demands for Inclusion of ACTA's Criminal IP Provisions in CETA

    PDF  | Print |  E-mail
    Thursday November 01, 2012
    Reports this morning from EDRI, a European digital rights group, indicate that Europe has now dropped demands to include ACTA-style intellectual property criminal provisions within the Canada - EU Trade Agreement. The inclusion of IP criminal provisions in CETA was the source of considerable outrage in Europe in the aftermath of the European Parliament's rejection of ACTA in early July.  EDRI reports that the European Council obtained support over the summer from member states to drop demands for the criminal provisions, fearing those provisions could lead to a European rejection of the treaty (the Dutch government has already indicated it will not support CETA if it includes ACTA provisions).

    The removal of ACTA's criminal provisions leave only two copyright-related question marks in CETA. First, the ACTA border measures provisions have yet to be determined as they are being discussed within the context of protection for geographical indications. Second, Canada is still seeking the inclusion of criminal anti-camcording rules. Canada adopted those rules in 2007 under significant pressure from the United States. Europe resisted their inclusion within ACTA, resulting in a provision that is optional rather than mandatory. While Canada is seeking a mandatory rule, it seems likely this is a (very weak) bargaining chip, rather than a serious attempt to require criminal anti-camcording measures. Canada may drop the demand during negotiations later this month over pharmaceutical patent reform. Regardless, the European Parliament's rejection of ACTA has clearly had a significant impact on CETA as the Internet and criminal provisions are now both apparently gone in the face of widespread European opposition.
    Tags:
    , ,
    Share: Slashdot, Digg, Del.icio.us, Newsfeeder, Reddit, StumbleUpon, TwitterTagsShare
     

    De Gucht Says "No Illusions" About Difficult CETA Issues

    PDF  | Print |  E-mail
    Wednesday October 31, 2012
    EU Commissioner Karel de Gucht says that there should be "no illusions" about the remaining difficult issues in the Canada - EU Trade Agreement, suggesting that completion by the end of the year remains uncertain. De Gucht indicated that CETA once included ACTA language, but says that has now been removed.
    Tags:
    , ,
    Share: Slashdot, Digg, Del.icio.us, Newsfeeder, Reddit, StumbleUpon, TwitterTagsShare
     

    The $2 Billion Big Pharma Giveaway in CETA: Can the Government Ignore Its Own Internal Analysis?

    PDF  | Print |  E-mail
    Thursday October 18, 2012
    The Canada - EU Trade Agreement has been the subject of conflicting reports on the inclusion of ACTA provisions, but there has been no doubt about the ongoing dispute over the agreement's patent rules. Given the EU demands for significant patent reforms, the issue has been set aside with the ministers expected to address it when they meet in November.

    For months, big pharmaceutical companies (known as Rx&D) and civil society/the generic pharmaceutical industry have been battling over the issue. Each has released public opinion surveys that purport to demonstrate support for their position (Rx&D, civil society). More important has been a study that concluded that the proposed reforms could add billions to annual Canadian health care costs along with reports that show that the large pharmaceutical companies failed to meet research and development commitments the last time the Canadian government acquiesced to patent reform demands.

    While Rx&D sought to downplay those studies (as did the government, which described these concerns as a myth), it now faces an internal government study conducted by Industry Canada and Health Canada that placed the costs of CETA patent reform as high as $2 billion per year. The $2 billion cost would significantly decrease the government's claims of likely economic gains from CETA and heighten provincial opposition, since the costs will be offloaded to provincial health care budgets.


    Tags:
    , ,
    Share: Slashdot, Digg, Del.icio.us, Newsfeeder, Reddit, StumbleUpon, TwitterTagsShare
    View
     
    << Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

    Results 9 - 12 of 72